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Huntington’s disease (HD) is a neurodegenerative disorder previously thought to be of primary neuronal
origin, despite ubiquitous expression of mutant huntingtin (mHtt). We tested the hypothesis that mHtt
expressed in astrocytes may contribute to the pathogenesis of HD. To better understand the contribution
of astrocytes in HD in vivo, we developed a novel mouse model using lentiviral vectors that results in selec-
tive expression of mHtt into striatal astrocytes. Astrocytes expressing mHtt developed a progressive pheno-
type of reactive astrocytes that was characterized by a marked decreased expression of both glutamate
transporters, GLAST and GLT-1, and of glutamate uptake. These effects were associated with neuronal dys-
function, as observed by a reduction in DARPP-32 and NR2B expression. Parallel studies in brain samples
from HD subjects revealed early glial fibrillary acidic protein expression in striatal astrocytes from Grade 0
HD cases. Astrogliosis was associated with morphological changes that increased with severity of disease,
from Grades 0 through 4 and was more prominent in the putamen. Combined immunofluorescence showed
co-localization of mHtt in astrocytes in all striatal HD specimens, inclusive of Grade 0 HD. Consistent with the
findings from experimental mice, there was a significant grade-dependent decrease in striatal GLT-1
expression from HD subjects. These findings suggest that the presence of mHtt in astrocytes alters glial glu-
tamate transport capacity early in the disease process and may contribute to HD pathogenesis.
INTRODUCTION
Huntington’s disease (HD) is a genetically dominant neurode-
generative disorder characterized by psychiatric symptoms,
progressive chorea and cognitive decline, with marked neuro-
pathological involvement of the basal ganglia (1). HD is
caused by the expansion of a polyglutamine repeat in the
protein huntingtin (Htt). Wild-type and mutant Htt (mHtt) are
expressed in many cell types. Although abnormalities in periph-
eral tissues have been recently reported in HD (2), the most
striking changes are found within the neostriatum, in which
there is gross atrophy of the caudate nucleus and putamen
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accompanied by marked neuronal loss (3). In particular, striatal
GABAergic, medium-sized, spiny projection neurons (MSNs)
are affected early and most severely in the disease (4,5). The
mechanisms causing mHtt gain and/or loss-of-function
remain unclear and include transcriptional modulation,
protein aggregation, proteosomal dysfunction, axonal transport
deficit, mitochondrial dysregulation, and excitotoxicity (6,7).
Despite the fact that MSNs are the primary neostriatal target
of the mutation, the selective expression of mHtt in MSNs
does not induce significant locomotor deficits and striatal neu-
ropathology, suggesting that cell–cell interactions are necess-
ary for striatal pathogenesis to occur (8). In particular,
corticostriatal glutamatergic inputs may play a key role (9). In
addition, glial cells and notably astrocytes could also be
involved in pathological cell–cell interactions. Astrocytes via
their glutamate transporters GLAST and GLT-1 regulate extra-
cellular glutamate levels (10), neuronal transmission (11) and
energy metabolism (12). Alteration of these functions has
long been suggested to contribute to the pathophysiology of
HD. Mutated Htt is expressed in all glial cells, but very little
is known regarding their possible function. Original neuro-
pathological analyses of post-mortem brains of HD patients
revealed astrogliosis of increasing magnitude in the course of
the disease (3). As in many other neurodegenerative diseases,
it has been proposed that these glial changes mainly reflect a
response to neuronal death and/or dysfunction. However,
recent in vitro evidence suggests that expression of mHtt in
astrocytes may directly affect astrocyte function, exacerbating
the dysfunction of vulnerable striatal neurons (13). To better
understand the contribution of astrocytes in HD in vivo, we
developed a novel mouse model using lentiviral vectors that
results in selective expression of mHtt into striatal astrocytes.
Astrocytes expressing mHtt progressively developed a reactive
phenotype and showed a marked decreased expression of both
glutamate transporters and a reduction in glutamate uptake.
These effects were associated with neuronal dysfunction, as
observed by a reduced DARPP-32 and NR2B expression, two
markers of MSNs. Consistent with the above findings, a com-
prehensive histological analysis revisiting potential astrocyte
reactivity in post-mortem brains of HD patients showed the
presence of astrogliosis in Grade 0 caudate nucleus and vali-
dated the co-localization of mHtt in astrocytes along with a
grade-dependent reduction in GLT-1. These results collectively
suggest that mHtt activates astrocytes and impairs their
function, reducing glutamate uptake and contributing to striatal
dysfunction in HD.
RESULTS
Selective expression of mHtt in neurons and astrocytes
of mice striatum using two different lentiviruses
Four weeks after injection of lentiviral vectors encoding the
first 171 amino acids of the human Htt with 82 glutamines
(Htt171-82Q) in adult mouse striatum, mHtt aggregates were
detected by immunofluorescence on brain coronal sections.
These aggregates co-localized with the neuronal nucleus
marker NeuN (Fig. 1B), but not with the astrocytic marker
GS, using the G protein envelope of the vesicular stomatitis
virus (VSV-G)-pseudotyped lentiviral vector. However,
when the Mokola-pseudotyped lentiviral vector including the
four copies of the miR124T was injected into mouse striatum,
fewer aggregates were observed and they co-localize with GS
and not with NeuN (Fig. 1B). The results show that these gene
transfer systems allow for a selective expression of a short
fragment of mHtt in either striatal neurons or astrocytes. We
also present evidence that the Mokola-miR124T lentiviral
vector did not transduce microglia using an antibody directed
against Iba1 (data not shown).
We next studied the consequence of such expression on
astrocyte reactivity using immunofluorescent staining of
glial fibrillary acidic protein (GFAP). Neuronal expression
of Htt171-82Q led to a marked increase in GFAP immunos-
taining, with astrocytes adopting the prototypical features of
reactive astrocytes (Fig. 1C). Selective expression of
Htt171-82Q into astrocytes also induced an increase in
GFAP expression. No astrocyte activation was noted when
Htt171-18Q was expressed into neurons or astrocytes,
suggesting that such activation was not due to the infection
of cells by a lentiviral vector. This result indicates that
expression per se of Htt171-82Q into astrocytes alters
their phenotype. We therefore studied the time course of
the morphological changes induced by Htt171-82Q into
astrocytes.
Expression of Htt171-82Q in astrocytes changes
their morphology
To better characterize the morphological changes and to
follow the fine astrocytic processes that are not stained by
GFAP, we co-injected a Mokola-pseudotyped lentiviral
vector encoding green fluorescent protein (GFP) with the
Mokola-pseudotyped vector encoding Htt171-82Q or 18Q.
As previously noted with a VSV-G-pseudotyped vector
(14), we observed that the injection of two different
Mokola-pseudotyped vectors co-infected the majority of astro-
cytes within the injected region (data not shown). At 4 weeks
after injection, GFP expression revealed the astrocytic pro-
cesses, including the fine distal arbors (Fig. 2A), as we
reported previously (15). Four to 12 weeks after intrastriatal
injection, GFAP staining increased in astrocytes expressing
Htt171-82Q, when compared with those expressing Htt171-
18Q. Since reactive astrocytes are characterized by hypertro-
phy (16), we measured the somal area of astrocytes expressing
GFP at 4, 8 and 12 weeks after lentiviral vectors injection. At
all time points, the vast majority of astrocytes (85%) expres-
sing Htt171-18Q displayed a somal area ,60 mm2 with only
a small fraction (15%) having an area .60 mm2. The
proportion of larger astrocytes (somal area .60 mm2) signifi-
cantly increased up to 47% at 12 weeks when they expressed
Htt171-82Q (Fig. 2B). Since resting astrocytes can proliferate
after injury (17), we counted the total number of dividing
cells in the entire neostriatum at 12 weeks. We did not
observe significant proliferation, since the total number of
5-bromo-2-deoxyuridine (BrdU)-incorporating cells was not
statistically different between 18 and 82Q (672+ 86 versus
593+ 71 cells). We did note, however, a mild but significant
decrease of the number of GFP-positive astrocytes at 12 weeks
(mean number of cells per field: 12.7+ 1.2 for 18Q versus
9.1+ 1.1 for 82Q, P ¼ 0.041).
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Htt171-82Q in astrocytes decreases the expression and
function of astrocytic glutamate transporters
Dysfunction of glutamate transport has been reported in
different mouse models of HD. Whether this finding is
indirectly linked to neuronal dysfunction or a direct conse-
quence of the expression of mHtt into astrocytes has not
been determined in vivo. We injected mice with a mixture
of selected lentiviral vectors that allow for a restricted
expression of mHtt and GFP into either neurons or astrocytes.
At selected time points after injection, either immunofluores-
cence staining was performed on striatal sections or fresh
GFP-positive striatal tissues were collected and analyzed.
Six weeks after injection of the VSV-G-pseudotyped lentiviral
vector, the immunofluorescence staining of GLAST and
GLT-1 did not change when Htt171-82Q was expressed into
neurons. This result suggests that glutamate transport is not
altered by neuronal Htt171-82Q (Fig. 3A and B). We next
studied brain samples from mice injected with the Mokola-
miR124T lentiviral vector, allowing for specific astrocytic tar-
geting. Quantification of the immunofluorescence staining of
GLT-1 showed a significant and progressive decrease reaching
a maximum at 12-week post-injection (245%). Immunofluor-
escence staining of GLAST also decreased, but the effect was
only statistically significant 12-week post-injection (238%;
Fig 3C and D). These changes were not the consequence of
a global astrocytic dysfunction, since the expression of
S100b quantified by immunofluorescence was not modified
by Htt171-18Q (data not shown). Twelve-week post-injection,
real-time quantitative polymerase chain reaction (RT-qPCR)
performed from striatal GFP-positive samples showed a
decrease in GLT-1 and GLAST mRNA levels in the
Htt171-82Q-injected side compared with Htt171-18Q (28
and 20% respectively; Fig. 3E). mRNA levels of the neuronal
glutamate transporter EAAC1 and of the astrocytic aquaporin
4 (AQP4) did not change. Using primers that recognize both
mouse and human Htt, we were able to show that the
mRNA level of Htt171-82Q was 2.4 times greater than the
endogenous level of Htt (0.038+ 0.004 versus 0.017+
0.001, P , 0.01, Student’s t-test), indicating that the effects
we observed were not the consequence of a massive overex-
pression of Htt171-82Q into astrocytes. We also performed
immunoblotting (Fig. 3F and G) on fresh samples from the
GFP-positive area 12 weeks after lentiviral vector injection.
Densitometric analysis of GLT-1 and GLAST signals
showed a respective decrease of 44 and 55% (Fig. 3E).
Expression of glutamine synthetase (GS) was also significantly
decreased by 38%. Finally, 3H-D-aspartate uptake performed
on synaptosomal fractions 12-week post-injection revealed a
functional loss of glial transporters by 40% (Fig. 3H).
Together, these results suggest that glutamate transport dys-
function is a direct consequence of Htt171-82Q in astrocytes.
Overexpression of GLT-1 partly rescues
the astrocyte phenotype
To determine whether the loss of glutamate transport capacity
by Htt171-82Q-expressing astrocytes was directly detrimental
to their phenotypic changes, we overexpressed GLT-1, using
Figure 1. Characterization of the mouse model expressing Htt171-82Q in astrocytes. (A) Scheme of the proviral vector form of lentiviral vector modified to carry
the four copies of the miRNA target sequences (miR124T). Lentiviral vectors were pseudotyped with VSV-G or Mokola. (B) Double immunofluorescent staining
with either GS (green) and Huntingtin-2B4 (red) or with NeuN (green) and 2B4 (red) confirmed that the lentiviral vector pseudotyped with VSV-G induced the
expression of mHtt (observed as aggregates) in NeuN-positive neurons and not in GS-positive astrocytes, whereas the vector pseudotyped with Mokola and
including miR124T induced the expression of mHtt in GS-positive astrocytes and not in NeuN-positive neurons. (C) When Htt171-82Q is expressed in
neurons, astrocytes adopt the prototypical features of reactive astrocytes. Expression of Htt171-82Q in astrocytes leads also to a marked increase in GFAP
expression but the cells do not lose their domain organization. Scale bars (B), 50 mm (C) 20 mm.
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the Mokola-miR124T lentiviral vector, in astrocytes expres-
sing Htt171-82Q. Nine weeks after injection, the expression
of GLT-1 was increased by 64% and the proportion of reactive
astrocytes (somal area .60 mm2) was significantly decreased
from 48–30% (Fig. 4). This result suggests that overexpres-
sion of GLT-1 partially rescued astrocyte dysfunction.
Htt171-82Q in astrocytes decreases the expression of
DARPP-32 and NR2b in neurons
Dopamine and adenosine 3′,5′-monophosphate-regulated
phosphoprotein (32 kDa) (DARPP-32), is highly enriched in
striatal medium spiny neurons. Its down-regulation is an
early marker of neuronal dysfunction in HD (18,19).
NMDAR-NR2B subunits are a major NR2 subunit predomi-
nantly expressed extrasynaptically by these striatal medium
spiny neurons (20,21). We observed a significant decrease in
the immunofluorescence staining of DARPP-32 and NR2B
12 weeks after the expression of Htt171-82Q into astrocytes
(215 and 225% versus Htt171-18Q, respectively, P ,
0.05) (Fig. 5). These results indicate that Htt171-82Q-induced
astrocyte dysfunction can impact neuronal function.
Grade-dependent increased GFAP immunoexpression
in human HD striatum
Since our data obtained in the mouse model suggest that astro-
cytic mHtt alters the phenotype of astrocytes, we sought to
re-evaluate the time course of the GFAP immunoexpression
in 10 mm paraffin-embedded human HD neostriatal specimens
by using well-defined HD stages, particularly Grade 0 patients.
Immunoexpression of GFAP was present in the neostriatal
specimens in all grades of severity (0–4) from HD subjects
(Fig. 6). GFAP expression became increasingly more intense
with a greater number of astrocytes expressing GFAP, with
increasing grade of severity. As previously reported, reactive
astrocytosis was first present in the dorsal striatum and
coursed to the ventral striatum in a dorso-ventral gradient
with greater disease progression (3). We observed the presence
of fibrillary astrocytosis in the dorsal striatum in Grade 0 HD
subjects. There was a significant grade-dependent increase in
GFAP immunoreactivity first present in Grade 0 specimens
with a continued increase in GFAP expression through
Grade 4 specimens, when compared with normal control
tissues (control versus G1, P , 7 × 1024; control versus G2,
Figure 2. Time course of the morphological changes in astrocytes expressing mHtt. (A) Increase in GFAP immunostaining (red) in astrocytes co-infected with
Htt171-82Q or 18Q and GFP (green) at 4- to 12-week post-injection. (B) At 12 weeks, astrocytes expressing mHtt become hypertrophic with larger processes and
withdraw most of their finer processes. (C) Quantification of the somal area of GFP-positive astrocytes. At 4, 8 and 12 weeks, the vast majority of the astrocytes
expressing Htt171-18Q have a somal area ,60 mm2. The proportion changes with time for astrocytes expressing Htt171-82Q, and at 12 weeks, half of the astro-
cytes have a somal area .60 mm2 (Student’s paired t-test versus respective 18Q control, ∗∗∗P, 0.001; ∗∗P , 0.01). Scale bars 20 mm.
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P, 8 × 10210; control versus G3, P, 6 × 10210; control
versus G4, P, 1 × 10210). In addition, densitometric analy-
sis showed significant differences between dorsal and ventral
regions within each grade (G1, P , 0.0214; G2, P , 9.7 ×
1025; G3, P, 5.5 × 1026; G4, P , 0.0282). Although
qualitative data from the two Grade 0 HD cases may be too
small for a meaningful interpretation, these cases are very
rare pathological samples and may provide pathophysiological
direction in HD and, as such, these findings warrant attention.
GFAP immunostaining in 50 mm-thick free-floating tissue
Figure 3. (A and B) Expression of Htt171-82Q in neurons does not change the level of expression of astrocytic glutamate transporters GLT-1 and GLAST.
Immunostaining of GLT-1 or GLAST was performed 6 weeks after injection of VSV-G-Htt171-18Q or 82Q in mice striatum (n ¼ 5; Student’s paired t-test,
P ¼ 0.53 and 0.69, respectively). (C) mHtt in astrocytes decreases the expression and function of glutamate transporters GLAST and GLT-1. Immunofluores-
cence of GLT-1 and GLAST in the area expressing Htt171-82Q compared with the area expressing Htt171-18Q at 12 weeks. (D) Htt171-82Q significantly
decreases the expression of GLT-1 at all time points and of GLAST only at 12 weeks (n ¼ 6 at each time points; Student’s paired t-test; ∗P , 0.05; ∗∗∗P,
0.001). (E) RT-qPCR of GLT-1, GLAST, EAAC1 and AQP4 on striatal GFP-positive area at 12 weeks relative to cyclophiline mRNA level (n ¼ 5; Student’s
paired t-test, ∗P , 0.05). (F and G) Quantification of immunoblots confirmed the decreased expression of both GLT-1 and GLAST and showed a significant
decrease in GS. (Student’s paired t-test, n ¼ 8, 5 and 8, respectively). (H) 3H-aspartate uptake on synaptosomes from GFP-positive striatal samples. Expression
of Htt171-82Q significantly decreases glutamate uptake (239%) at 12 weeks (Student’s t-test, ∗P ¼ 0.02).
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sections confirmed our findings of increased fibrillary astrocy-
tosis in Grade 0 HD striatal specimens, in comparison to non-
neurological control specimens (Fig. 7). Astroglial morpho-
logical changes occurred as fibrillary astrogliosis became
more fulminant with disease severity, with greater immuno-
reactive intensity, a thickened more tortuous arborization
and increased somal size (Fig. 7). Using Nomarski optics,
we show that in normal control specimens, astrocytes were
lightly immunostained and presented with abundant short
thin branches and a lace-like pattern that formed rounded
arborizations. In Grade 0 cases, increased immunointensity
occurred in astrocytes, with the absence of the fine lace-like
appearance. Markedly increased changes in astrocytes
occurred with greater disease severity, until the dysmorphic
reactive astroglia became almost unrecognizable in the most
severe grade (Fig. 7). Although fibrillary astrocytosis was
present in both the caudate nucleus and the putamen in all
grades, these morphological changes were more prominent
in the putamen, in contrast to the caudate nucleus, particularly
with regard to somal size and arbor thickness (Fig. 8). This
finding suggests a different degenerative process in these
areas of the neostriatum.
Co-localization of GFAP and Htt immunoexpression
in striatal astroglia
Combined immunofluorescence of GFAP and Htt in graded
cases from HD subjects showed co-localization in all grades
of HD severity (Fig. 9). Two-dimensional immunofluores-
cence showed marked co-localization of each protein in
severe grade cases, with moderate co-localization in lower
grade cases, especially Grade 0. In order to ensure the validity
of our findings, we performed confocal analysis of tissue speci-
mens. These studies were consistent with the two-dimensional
Figure 4. Overexpression of GLT-1 improves mHtt-induced morphological changes of astrocytes. (A) Scheme of the proviral vector form of the lentiviral vector
modified to carry the four copies of the miRNA target sequences and encoding GLT-1-HA. A lentiviral vector encoding GLT-1-HA or PBS–BSA was injected
3 weeks after Htt171-82Q + GFP in the same injection site and morphological analysis was performed 9 weeks after. (B and C) In the area immunopositive for
HA (blue) and GFP, GLT-1 expression is significantly increased by 64% (n ¼ 4, Student’s paired t-test, ∗P ¼ 0.013). (D) GFAP immunostaining decreases when
GLT-1 is overexpressed in mHtt-transduced astrocytes. (E) Quantification of GFP-positive somal area in the HA-positive area 9 weeks after GLT-1 overexpres-
sion shows that the proportion of astrocytes with somal area .60 mm2 decreases from 48 to 30% (Student’s t-test, ∗P ¼ 0.028). Scale bars 10 mm.
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interpretation (Fig. 9). Htt/GFAP co-localization in striatal
grey matter from Grade 0 HD is a novel finding and suggests
that the presence of Htt aggregates in astroglia is an early and
progressive event that may be associated with the pathophy-
siology of the disease.
Down-regulation of GLT-1 immunoexpression in striatal
specimens from HD subjects
In conjunction with the experiments reported above in mice
expressing Htt171-82Q in astrocytes only, we performed an
immunohistochemical analysis of GLT-1 in neostriatal speci-
mens from HD subjects. There was a grade-dependent loss of
GLT-1 present in Grade 0 specimens with a continued loss of
tissue protein expression through Grade 4 specimens, when
compared with normal control specimens (control versus G1,
P, 9 × 1026; control versus G2, P , 9 × 1026; control
versus G3, P , 9 × 1026; control versus G4, P , 9 × 1026)
(Fig. 10).
DISCUSSION
Non-cell autonomous degeneration is now thought to operate
in an increasing number of neurodegenerative diseases, includ-
ing polyQ repeat disorders (22). In addition to neuron–neuron
interactions, neuron-glial cell and in particular neuron-
astrocyte cross-talk are implicated in some degenerative
processes (23). Animal models developed to evaluate the
contribution of astrocytes are usually obtained by driving the
expression of the mutant protein with the specific astrocytic
promoter gfa2, a 2.2 kDa human GFAP promoter (24,25).
This promoter contains regulatory elements activated during
astrogliosis (26) and, as such, expression levels of the trans-
gene may depend on the phenotype of the astrocyte. We
have employed a different gene transfer strategy using our
newly developed lentiviral vector (15) to express the first
171 amino acids of the human Htt with normal (18) or
expanded (82) glutamine repeat into striatal astrocytes, under
the control of the mouse phosphoglycerate kinase 1 promoter.
This experimental approach led to the expression of
Htt171-82Q or 18Q in a select subpopulation of striatal astro-
cytes. On the basis upon our recent observation (15), we
assumed that 37 500 astrocytes were transduced by a
single injection of 3 ml of the Mokola-miR124T lentiviral
vector. Of interest, 3400 neurons were also transduced,
despite a decreased expression in the transgene by .50%
due to the repression induced by the mir124T (15). We, there-
fore, concluded that the residual expression of Htt171-82Q
into neurons using Mokola-miR124T lentiviral vector was
negligible. At 4 weeks after injection, mHtt aggregates were
observed in astrocytes and not in neurons, confirming the
selectivity of the viral vector. The fact that mHtt can form
aggregates in astrocytes is supported by previous observations
of glial aggregates in R6/2 mice expressing HD exon 1 protein
and Hdh CAG(150) knock-in mice expressing full-length mHtt
(13). We also observed co-localization of Htt and GFAP in
striatal astrocytes from HD subjects. Although similar findings
have been previously reported (13), they have not been
observed in the striatal grey matter or in low-grade specimens
from HD patients. Htt/GFAP co-localization in Grade 0 HD is
a novel finding and suggests that the presence of Htt in astro-
glia is an early and progressive event that may be associated
with the pathophysiology of the disease.
In response to CNS pathology, astrocytes undergo a charac-
teristic change in appearance, hypertrophy of their soma and
cellular processes, a phenomenon referred to as reactive
gliosis (16). During chronic diseases, reactive astrocytes are
evenly distributed and have randomly orientated processes, a
reversible phenomenon called isomorphic gliosis. Original
neuropathological analyses of post-mortem brains of HD
patients have revealed reactive gliosis starting in Grade 1
specimens and with increasing magnitude in the pathological
grades of the disease (3). As in many other neurodegenerative
diseases, it has been proposed that these glial changes are sec-
ondary to neuronal dysfunction and death. In the present
Figure 5. mHtt in astrocytes decreases the expression of neuronal markers DARPP-32 and NR2B. Twelve weeks after selective co-transduction of
Htt171-82Q + GFP in astrocytes in vivo, expression of DARPP-32 (A, C) and NR2B (B, D) was significantly decreased by 15 and 25%, respectively (Student’s
paired t-test, ∗P ¼ 0.046, ∗P ¼ 0.029). Scale bars 20 mm.
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studies, we observed an increased GFAP expression in the
dorsal striatum in each Grade 0 HD subject. Such early acti-
vation suggests that mHtt in astrocytes may contribute to
these phenotypic changes via intrinsic mechanisms. This
hypothesis is corroborated by our observation in mice expres-
sing mHtt only in striatal astrocytes that display a reactive
phenotype at 8 weeks after injection, despite the absence of
a marked neuronal dysfunction or death at this time. Acti-
vation of astrocytes was directly linked to Htt171-82Q
expression since no changes were observed with
Htt171-18Q. This result suggests that reactive gliosis may be
the result of an intrinsic reaction of astrocytes expressing
mutant proteins. We cannot rule out the alternative hypothesis
that the gliosis-like changes in mHtt-expressing astrocytes also
results from disturbances in extracellular glutamate load that
in turn lead to the astrogliotic changes. Although the corre-
lation between increased astrogliosis and neuronal loss has
long been a favored topic of discussion in HD, much less
attention has been brought forth with regard to the differential
expression of disease severity between the caudate nucleus
and the putamen. There has been some suggestion that prefer-
ential putaminal degeneration may be more fulminant in HD
(27,28). Our findings of greater astroglial hypertrophy and
dysmorphology in the putamen versus the caudate nucleus in
the same cases is consistent with these reports. Our results
also suggest that such differential vulnerability may be due
to a higher susceptibility of putaminal HD astrocytes.
It has long been hypothesized that excessive glutamatergic
signaling in the neostriatum may contribute to the pathophy-
siology of HD (29,30). Recent experimental evidence demon-
strates that the deafferentation of corticostriatal and
nigrostriatal pathways in the neostriatum of HD mice mitigates
striatal stress and neurodegeneration, ameliorating neuro-
pathological sequelae (9). Accordingly, neurons expressing
high levels of NMDA receptors are lost early in the striatum
of individuals affected with HD (31,32). In particular,
mutant Htt protein aggregation may result in impaired mito-
chondrial function (33) and increases the sensitivity of
neurons to excitotoxicity associated with the stimulation of
NMDA receptors harboring the NR2B subunits (21). Indeed,
degeneration is exacerbated in Hdh CAG(150) knock-in
mice overexpressing NR2B (34).
Astrocytic uptake of glutamate and the conversion of gluta-
mate to glutamine is the predominant mechanism of inactivation
of glutamate once released in the synaptic cleft. This uptake
involves two transporters, GLT-1 and GLAST, GLT-1 being
predominantly expressed in the striatum (10). We report,
herein, that expression of a short N-terminal fragment of mHtt
into striatal astrocytes is sufficient to decrease the expression
of both glutamate transporters in a time-dependent manner.
Expression levels of both mRNAs were also reduced, but less
markedly, suggesting that transcriptional and post-translational
mechanisms mediated by polyglutamine-expanded huntingtin
may contribute to the decreased expression of GLAST and
GLT-1 proteins. Such an effect was associated with a significant
reduction of glutamate uptake capacity by striatal synaptosomes
and with a decrease in GS expression. No change was observed
when Htt171-82Q was expressed in striatal neurons. Together,
these data suggest that the global impairment of the mechanisms
responsible for glutamate inactivation may be linked to the
expression of polyQ-expanded Htt in astrocytes and not in
neurons, as recently observed in transgenic mice that express
mutant N-terminal htt fragments under the GFAP promoter (35).
Figure 6. Representative GFAP immunohistochemistry–hematoxylin-stained
paraffin sections from the caudate nucleus in non-neurological control, Grade
0, Grade 1, Grade 2, Grade 3 and Grade 4 HD subjects. The array of photomicro-
graphs for each specimen group shows the ventral-most caudate nucleus and
dorsal-most caudate nucleus at low and high power. There was increased reac-
tive astrocytosis starting in the dorsal segment of Grade 0 cases with a dorso-
ventral progression of greater immunoreactive astrocyte activity with severity
of disease. Densitometric analysis showed significant differences between
grades and between dorsal and ventral regions within each grade. The magnifi-
cation bars in the low-power columns are 100 and 25 mm in the high-power
columns for the dorsal and ventral areas, respectively.
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Our results are consistent with a previously reported
decrease in GLT-1 in R6/2 transgenic mice (36,37) and
these findings may be due to the glial expression of mHtt.
We also show that the loss of GLT-1 protein is an early
event in human disease pathogenesis, showing a significant
reduction in Grade 0 HD human specimens, with a continued
grade-dependent loss of tissue protein expression of GLT-1 in
Grade 4 HD. This result suggests that our findings in mice
expressing the short N-terminal fragment of Htt parallel
those observed by the expression of the full-length Htt
protein. As we also observed in mice, such decreases may
result from transcriptional dysregulation, since GLT-1
mRNA has previously been shown to be reduced in HD
patients in more advanced grades (38). The impairment of glu-
tamate transport and recycling capacity was associated with a
significant decrease in the expression of two neuronal markers,
DARPP-32 and NR2B in our mouse model, indicating that the
selective expression of mHtt into astrocytes is sufficient to
alter neuronal function. DARPP-32 is an early marker of stria-
tal neuron dysfunction and is down-regulated by 4 weeks after
expression of mHtt into neurons (19) and in pre-symptomatic
transgenic HD mice (18,39). In these HD mice, the loss of
DARPP-32 is a consequence of transcriptional dysregulation
via the interaction of neuronal mHtt with the transcription
factor Sp1 (40). The NR2B subunit is a key mediator of the
excitotoxic damage elicited by mHtt expression (30).
NR2B-type NMDARs predominate at extra-synaptic sites on
the plasma membrane and are linked to pathways involved
in cell death (41). Their expression is altered in different
models of HD mice (42) and in human HD samples (38). Of
interest, increased activity of calpain was recently suggested
to contribute to the loss of NR2B-containing surface receptors
(43). Our result, however, identifies other mechanisms, likely
involving dysregulation of extracellular glutamate buffering,
which could contribute to the decreased expression of
DARPP-32 and NR2B in HD.
Impaired astrocytic glutamate uptake is recognized as a criti-
cal pathophysiological event in a number of neurodegenerative
diseases, including amyotrophic lateral sclerosis, spinocerebel-
lar ataxia type 7, some tauopathies and HD (22). As such, these
findings have implications for the development of potential new
therapies. Increasing the activity of glial transporters may there-
fore represent an obvious strategy. In the present study, selective
gene transfer of GLT-1 into striatal astrocytes ameliorates the
phenotype of astrocytes, but it remains to be determined
whether such an approach could slow disease progression in
transgenic HD mice. Of great interest, the b-lactam antibiotic
ceftriazone that up-regulates GLT-1 expression (44) amelio-
rates disease phenotype in HD mice (45). Our study highlights
the need for a therapeutic approach targeting both neurons and
glial cells in the context of HD.
MATERIALS AND METHODS
Animals
Seven-week-old male C57Bl6 mice (weight, 20 g; Charles
River, France) were used in this study. All experimental pro-
Figure 7. Nomarski optics using GFAP immunohistochemistry in thick (50 mm) tissue sections from the caudate nucleus in non-neurological control (A), Grade 0
(B), Grade 1 (C), Grade 2 (D), Grade 3 (E) and Grade 4 (F) HD subjects. Normal astrocytes present as faintly GFAP-stained cells with a short lace-like branching
pattern distributed symmetrically around the cell soma. With increasing disease progression, there was greater GFAP immunoreactivity, twisting and thickened
arbors, with larger somal size. The degree of astrogliosis became so great as to mask their individual appearance. The magnification bar in (A) represents
100 mm and is the same in all photomicrographs.
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cedures were performed in strict accordance with the rec-
ommendations of the European Commission (86/609/EEC)
concerning the care and use of laboratory animals.
Lentiviral vectors
To target the expression of mHtt into neurons, we used our
previously described self-inactivated lentiviral vectors pseudo-
typed with VSV-G and encoding the first 171 amino acids of
the human huntingtin gene (htt) with 18 or 82 CAG repeats
under the control of the mouse phosphoglycerate kinase 1 pro-
moter (19). To target the expression of the transgene into
astrocytes, we used our more recently developed vector (15).
This lentiviral vector is pseudotyped with the G protein envel-
ope of the Mokola lyssaviruses which displays a preferential
natural tropism toward astrocytes. To increase its selectivity,
we used the microRNA (miRNA) regulation pathway (46).
To avoid expression of the transgene in neurons, four copies
of a natural target sequence of the specific neuronal miR124
(miR124T) were inserted after the woodchuck posttranscrip-
tional regulatory element (Fig. 1A). For the visualization of
individually labeled cells, we also used a lentiviral vector
encoding GFP as described previously (15). Mouse GLT-1
cDNA (pcDNA3-myc-GLT-1 plasmid kindly provided by Dr
K. Tanaka) was inserted in the Mokola-pseudotyped lentiviral
vector including four copies of miR124T. The hemaglutinin
(HA) Tag (epitope YPYDVPDYA) was inserted in N-terminus
to distinguish its expression from the endogenous GLT-1. Len-
tiviral vectors were produced in 293T cells, using a four-
plasmid system, as previously described (47). The vectors
were resuspended in 1% bovine serum albumin (BSA) in
phosphate-buffered saline (PBS) and the virus particle
content was determined by p24 antigen ELISA (RETROtek,
Gentaur, Kampenhout, Belgium). The stocks were stored at
2808C until use.
Stereotaxic injections of lentiviral vectors
Mice were anesthetized with a mixture of ketamine (100 mg/
kg) and xylazine (10 mg/kg). Lentiviral vectors encoding the
htt gene with 18Q (wild type) or 82Q (mutated) were mixed
in PBS–1% BSA with vectors encoding GFP (3/1) to reach
a final concentration of 130 ng p24/ml. Suspensions of lenti-
viral vectors were injected into the striatum, using a 34 G
blunt-tip needle linked to a Hamilton syringe by a polyethy-
lene catheter. A total volume of 3 ml was injected at 0.2 ml/
min. The stereotaxic coordinates were: anteroposterior,
+1 mm; lateral, +1.8 mm from the bregma; and ventral,
22.5 mm from the dura, with tooth bar set at 0 mm. At the
end of the injection, the needle was left in place for 5 min
before being slowly removed. The skin was sutured and
mice were allowed to recover.
Real-time quantitative polymerase chain reaction
One millimeter-thick fresh brain slices were obtained using a
mouse brain matrix and 1.2 mm diameter punches were
sampled from the GFP-positive area under a fluorescent
microscope and were quickly frozen in dry ice and stored at
2808C. Total RNAs were extracted using a guanidinium
thiocyanate-based and phenol method. RT reaction was per-
formed on 400 ng of total RNA using Superscript II reverse
transcriptase (Invitrogen, Cergy, France) followed by treat-
ment with RNase H. Three nanograms of random-primed
cDNAs were processed for RT-qPCR using Mastercyclerw
ep realplex (Eppendorf, Le Pecq, France), and PCR products
Figure 8. Immunohistochemistry and immunofluorescence microscopy of the medial area of caudate nucleus (A and B) and putamen (C and D) in a Grade 3
subject. The degree of astroglial dysmorphology was greater in the putamen than in the caudate nucleus, with thickened and tortuous arbors along with increased
somal size. The magnification bar in (C) and (D) represents 100 mm.
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were quantified by measuring SYBR green fluorescent dye
incorporation. Values obtained for GLT-1, GLAST, EAAC1
and AQP4 were normalized to cyclophilin A expression
(Table 1). All experiments were carried out in triplicates for
each sample.
Immunoblotting
Fresh samples of striatal GFP-positive area were obtained as
mentioned above and were homogenized into 30 ml of lysis
buffer [50 mM Tris–HCl, pH 7.4, 100 mM NaCl, 1% SDS, and
protease inhibitor cocktail (1:200; Roche, Basel, Switzerland)].
Total protein content was determined with the BCA Protein
Assay Reagent (Thermo Scientific, Waltham, MA, USA),
according to the manufacturer’s instructions, and 15 or 20 mg
of total homogenate protein was subjected to SDS–PAGE
(4% stacking and 10% running gels) and transferred onto nitro-
cellulose membranes. Membranes were blocked by incubation
for 1 h with 5% non-fat milk powder in 25 mM Tris, pH 7.4,
150 mM NaCl and 0.1% Tween 20 (TBST buffer). Membranes
were incubated overnight at 48C with GLT-1, GLAST (rabbit;
1:5000, Frontier Sciences, Ishikari, Hokkaido, Japan), GFP
(rabbit, 1:100, Ozyme, Montigny le Bretonneux, France),
tubulin (mouse; 1:10 000; Sigma-Aldrich, St Louis, MO,
USA) or GS antibodies (mouse, 1:2000, BD Biosciences, Frank-
lin Lakes, NJ, USA). Membranes were washed and incubated
with peroxidase-conjugated secondary antibody (1:5000) for
1 h. Chemiluminescence reaction was carried out (ECL kit,
GE Healthcare, Uppsala, Sweden) and revealed using Kodak
BioMax ML film or CCD imaging system Fusion Fx7. Optical
density of immunoblots was measured using a computer-based
image analysis system (MCID Analysis, St Catharines, Ontario,
Canada).
Immunofluorescence and image analysis
Following an overdose of sodium pentobarbital, mice were per-
fused transcardially with 4% paraformaldehyde (PFA) in PB
0.1 M. Brains were post-fixed by incubation in the same solution
overnight and cryoprotected by incubation in a 30% sucrose sol-
ution during 48 h. Floating coronal brain sections (40 mm) were
cut on a freezing microtome, collected serially (interspace 240
or 280 mm), and stored at 2208C in a storing solution contain-
ing ethylene glycol, glycerol and PB 0.1 M, until analysis. Sec-
tions were blocked and incubated overnight at 48C with a
solution containing the primary antibody in 10% Normal goat
serum (NGS) 0.1 M PBS. The primary antibodies used were:
GFAP-Cy3 (1:500 GA-5 clone, mouse, Sigma-Aldrich), GS
(1:3000, rabbit, Sigma-Aldrich), GLAST or GLT-1 (1:5000,
rabbit, Frontier Sciences), Huntingtin 2B4 (1:600, mouse, Che-
micon, Billerica, MA, USA), HA (1:1000, mouse, Covance,
Princeton, NJ USA), S100b (1:3000, mouse, Sigma-Aldrich),
neuronal nuclear protein (NeuN; 1:500, mouse, Chemicon),
BrdU (1:100, rat, Sigma-Aldrich), NMDA12 (NR2B, goat,
1:50, Santa Cruz Biotechnology, Santa Cruz, CA, USA). They
were then incubated for 1 h at room temperature with fluorescent
secondary antibodies diluted at 1:500 (anti-rabbit AlexaFluor
594, anti-mouse AlexaFluor 488; anti-rat AlexaFluor 594, anti-
mouse AlexaFluor 633; Invitrogen). The sections were mounted
in FluorSave reagent (Calbiochem, Merck, Darmstadt,
Germany), covered with a cover slip and analyzed with confocal
microscopy (LSM 510, Zeiss, Le Pecq, France) using a ×63
Figure 9. Combined GFAP and huntingtin immunofluorescence in the medial caudate nucleus in Grade 3 and Grade 0 HD subjects. Two-dimensional analysis
showed overlap of each of the antisera (GFAP, red; huntingtin green; and merged figures, yellow) (A). Confocal immunofluorescence of Grade 0 and Grade 3
showed definitive co-localization throughout the tissue specimens (B). The magnification bar represents 20 mm.
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objective. Stack images were taken in the GFP-positive area
using the same settings for all conditions. The fluorescence
intensity of GLAST and GLT-1 staining was measured using
Morpho Expert software (Explora Nova, La Rochelle,
France). Somata of astrocytes were extracted by thresholding
using Morpho Expert software and their cross-section areas
were measured and classified into two categories: ≤60 and
.60 mm2 [corresponding to a mean diameter of 9 mm, the
typical diameter of quiescent astrocytes (48)].
BrdU incorporation
Mice were injected with BrdU (Sigma, France) during 3 con-
secutive days (one intraperitoneal injection/day, 50 mg/kg,
0.1 M NaOH in saline). Mice were then perfused with 4%
PFA in PB 0.1 M and sections were processed as described
above. Immunostaining of BrdU was performed on brain sec-
tions after the following specific pre-treatment: 5 min in 3%
H2O2, 10% methanol in 0.1 M PBS. Sections were rinsed, incu-
bated 30 min in 2 N HCl, 0.5% Triton X-100 in 0.1 M PBS at
378C and washed in 0.1 M borate buffer (pH 8.6). Then sec-
tions were processed as described above.
3H-Aspartate uptake on synaptosomes
Tritiated [3H]-D-aspartate uptake assays into synaptosomes
were performed according to (49). Fresh samples of striatal
GFP-positive area were obtained as mentioned above and
were homogenized with a glass–glass homogenizer in
ice-cold isolation medium (310 mM sucrose and 10 mM
HEPES, pH 7.4), followed by centrifugation at 1000g for
5 min. The supernatant was collected and centrifuged at
20 000g for 20 min to obtain the crude synaptosomal P2
pellet. Protein concentration was determined by BCA kit
(Thermo Scientific). P2 pellet were resuspended at a protein
concentration of 0.75 mg/ml in either HEPES-buffered saline
(10 mM HEPES, 5 mM Tris base, 140 mM NaCl, 2.5 mM KCl,
1.2 mM CaCl2, 1.2 mM MgCl2, 1.2 mM K2HPO4 and 10 mM
glucose, pH 7.4) for the specific uptake or in HEPES-buffered
Na+ free (HB-Na+ free) (10 mM HEPES, 5 mM Tris base,
140 mM choline-Cl, 2.5 mM KCl, 1.2 mM CaCl2, 1.2 mM
MgCl2, 1.2 mM K2HPO4 and 10 mM glucose, pH 7.4) for the
non-specific uptake. Synaptosomal pellets (23 mg each) were
incubated 7 min with 100 mM D-aspartate and 0.25 mCi
D-3H-aspartate at room temperature. Reactions were terminated
by filtration followed by rapid washing with ice-cold HB-Na+
free. Radioactivity retained on the filters was determined by
scintillation counting. In all uptake experiments, the radioac-
tivity retained after incubation in HB-Na+ free was used to
correct all data to represent Na+-dependent uptake.
Human brain tissue specimens
Post-mortem striatal tissue specimens from 25 adult-onset HD
patients (2 Grade 0 subjects; 3 Grade 1 cases, 5 Grade 2 cases,
9 Grade 3 cases and 6 Grade 4 cases; mean age of death, 66.7
years; range, 59–70 years) and 8 age-matched patients without
any known neurological symptoms (mean age, 68.9 years;
range 60–78 years) were dissected fresh and placed in cold
(48C) 2% PFA–lysine–periodate solution for 24–36 h.
Brain tissue specimens were collected at the Bedford Veterans
Figure 10. Immunohistochemical expression of GLT-1 in the caudate nucleus
from control and Grade 0–4 HD tissue specimens showed marked reduction of
GLT-1 in a grade-dependent manner from HD tissue specimens, in compari-
son to age-matched normal control specimens (A). Densitometric analysis of
GLT-1 immunofluorescence showed significant grade-dependent reductions
in GLT-1, with significant differences between grades (B). The magnification
bar represents 200 mm.
Table 1. Oligonucleotide sequences used for RT-qPCR
GLAST-F TCTCCAGTCTCGTCACAGGAATG
GLAST-R TGCCAATCACCACAGCAATG
GLT1-F GGCAATCCCAAACTCAAGAAGC
GLT1-R GTCACTGTCTGAATCTGCTGGAAAC
EAAC1-F ATGTGCTACATGCCGATTGG
EAAC1-R CTCAGGACAGTGGCCATGTAAA
AQP-4-F TTGGACCCGCAGTTATCATG
AQP-4-R GCGACGTTTGAGCTCCACAT
Htt-F CCGCTGCACCGACCAAAGAA
Htt-R ATTTCTGAGAGACTGTGCCA
CYCLO-F ATGGCAAATGCTGGACCAAA
CYCLO-R GCCTTCTTTCACCTTCCCAAA
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Administration Medical Center Brain Tissue Archive. The
post-mortem intervals did not exceed 18 h (mean time,
12.2 h; range, 4–18 h) and were similar for controls and HD
patients. CAG repeat length analysis was performed on the
HD specimens (mean number of CAG repeats, 43.8). The
range of CAG repeats in the adult-onset HD patients was
41–48. Each HD patient had been clinically diagnosed
based on known family history and phenotypic symptoms of
HD. The diagnosis of HD was confirmed by neuropathological
examination and graded by severity (3). Fixed striatal tissue
blocks were rinsed in 0.1 M sodium phosphate buffer, and
placed in cold cryoprotectant in increasing concentrations of
10 and 20% glycerol, 2% DMSO solution for 24–36 h.
Frozen serial sections of the striatal tissue blocks from the
anterior commissure to the rostral extent of the globus pallidus
were cut at 50 mm intervals in the coronal plane and placed
within a six-well collection container. The cut sections were
stored in 0.1 M sodium phosphate buffer with 0.08% sodium
azide at 48C for subsequent immunocytochemistry, immuno-
fluorescence and combined immunofluorescence methods for
GFAP, GLT-1 and huntingtin antibodies. Contiguous tissue
blocks were processed for paraffin embedding and specimens
were cut at 10 mm and subsequently stained for GFAP and
hematoxylin. Tissue sections were examined using a Nikon
Eclipse E800 microscope with a Spot RT digital camera
using light, Nomarski, and fluorescent optics.
Immunocytochemistry
Immunohistochemical localization of antibodies to GFAP
(1:500 GA-5 clone, mouse, Sigma), GLT-1 (1:5000, rabbit,
Frontier Sciences) and Huntingtin 2B4 (1:600, mouse, Chemi-
con) was performed by using a conjugated second antibody
method. Tissue sections from human striatum were pre-
incubated in an absolute methanol and 0.3% hydrogen per-
oxide solution for 30 min, washed (three times) in PBS (pH
7.4) for 10 min each, placed in 10% NGS (GIBCO) for 1 h,
incubated free-floating in primary antiserum at room tempera-
ture for 12–18 h (all dilutions of primary antisera above
included 0.08% Triton X-100 and 2% NGS), washed (three
times) in PBS for 10 min each, placed in horse radish
peroxidase-conjugated goat anti-rabbit IgG (1:300 in PBS,
Boehringer Mannheim, Indianapolis, IN, USA) or goat anti-
mouse IgG (1:300 in PBS, Boehringer Mannheim), washed
(three times) in PBS for 10 min each and reacted with
3,3′-diaminobenzidine HCl (1 mg/ml) in Tris–HCl buffer
with 0.005% hydrogen peroxide. Specificity for the antisera
used in this study was examined in each immunochemical
experiment to assist with interpretation of the results. This
examination was accomplished by using blocking peptides
or by omission of the primary antibody to determine the
amount of background generated from the detection assay.
Fluorescent immunocytochemistry
Immunofluorescence for GFAP and mHtt was performed on
human striatal HD and normal control tissue specimens.
Immunofluorescence was performed as described previously
(50). Striatal sections were incubated with anti-mHtt antibody
(1:500, mouse, Chemicon) in Tris–HCl buffer containing
0.3% Triton X-100 for 24–72 h at 48C. Sections were then
rinsed (three times) in PBS, incubated in the dark with horse
anti-mouse FITC conjugate for 2 h at 208C (Boehringer Man-
nheim; 1:200), rinsed (three times) in PBS and incubated with
Cy3-conjugated anti-GFAP (1:500 GA-5 clone, mouse,
Sigma) for 24–72h at 48C. Sections were wet-mounted and
coverslipped with 50% glycerol. Identical microscopic fields
were immediately photographed with a Nikon Eclipse E800
fluorescent microscope, delineating the location of GFAP
and mHtt immunoreactivities within the same striatal
section. The fields were merged and co-localization was ana-
lyzed.
Confocal image analysis
Digital imaging analysis was performed and images were cap-
tured at 0.25 mm intervals, and stacks were deconvoluted with
a constrained iterative algorithm, using a cooled charge-
coupled device camera (Retiga-2000R: Q-Imaging). Optical
sections were captured using NIS-Elements AR (Nikon Instru-
ments Inc, Melville, NY, USA) and processed using a 3D
deconvolution module. The spatial distribution of Htt and
GFAP in the caudate nucleus from HD subjects was deter-
mined using confocal microscopy and an image analysis
program (Auto Quant 3D, MediaCybernetics, Inc., Bethesda,
MD, USA). We analyzed a series of 15–20 confocal layers
representing fluorescence data from striatal astrocytes and sub-
sequently developed an abstract image that provided the
results.
Quantification
Densitometric analysis of GFAP and GLT-1 immunofluores-
cence was performed with the experimenter blinded to
disease conditions on multiple rendered images selected by
the imaging software system from human caudate nucleus
using Image-Pro Plus (MediaCybernetics, Inc.), using inverted
microscopic images to measure the intensity of immunostain-
ing.
Statistical analysis
Results are expressed as mean values+SEM. Statistical
analysis included paired (for left–right comparisons) and non-
paired Student’s t-test. The partition ratio obtained from somal
area values (i.e. proportion) was normalized using the arcsine
transformation before performing paired Student’s t-test (51).
Neuropathological data were compared by ANOVA followed
by post hoc Dunnett’s test (Statistica, Statsoft, France). The
significance level was set at P , 0.05.
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